Abstract
Introduction: Recent studies have shown modified cyclobutene derivatives as potent anti- tubercular agents, and the discovery of drugs against strains of Mycobacterium tuberculosis is still a crucial challenge in the modern world.
Objective: The objective of the present study is to design and perform molecular docking studies and in-silico analysis of some novel cyclobut-3-ene-1,2 Dione derivatives with the aim of creating new, potential Mtb ATP synthase inhibitors.
Materials and Methods: The structures of 24 compounds of diamino-substituted cyclobut-3-ene-1,2 Dione derivatives against Mtb ATP synthase were drawn using ChemSketch. Further, molecular docking and in-silico studies for the prediction of drug-likeness and pharmacokinetic parameters were carried out.
Results: The docking studies of the novel compounds were done, and they had a better docking score with a good binding affinity towards the protein molecule. The synthesized compounds also comply with the in-silico prediction of drug-likeness and pharmacokinetic parameters and have shown good activity against Mtb ATP synthase.
Conclusion: The current study shows that the cyclobut-3-ene-1,2 Dione derivatives can serve as a better lead molecule against Mtb ATP synthase and can be involved in further drug discovery.
Keywords: Cyclobut-3-ene-1, 2 dione derivative, Mtb ATP synthase, pyridazine, molecular docking studies, in-silico studies, 1c17.
Graphical Abstract
[1]
Appleton DR, Pearce AN, Copp BR. anti-Tuberculosis natural products: Synthesis and biological evaluation of pyridoacridine alkaloids related to ascididemin. Tetrahedron 2010; 66(27-28): 4977-86.
[http://dx.doi.org/10.1016/j.tet.2010.05.033]
[http://dx.doi.org/10.1016/j.tet.2010.05.033]
[2]
Banerjee DR, Biswas R, Das AK, Basak A. Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis. Eur J Med Chem 2015; 100: 223-34.
[http://dx.doi.org/10.1016/j.ejmech.2015.06.007] [PMID: 26092447]
[http://dx.doi.org/10.1016/j.ejmech.2015.06.007] [PMID: 26092447]
[3]
Brown JR, North EJ, Hurdle JG, et al. The structure–activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg Med Chem 2011; 19(18): 5585-95.
[http://dx.doi.org/10.1016/j.bmc.2011.07.034] [PMID: 21840723]
[http://dx.doi.org/10.1016/j.bmc.2011.07.034] [PMID: 21840723]
[4]
Cappoen D, Jacobs J, Nguyen Van T, et al. Straightforward palladium-mediated synthesis and biological evaluation of benzo[j]phenanthridine-7,12-diones as anti-tuberculosis agents. Eur J Med Chem 2012; 48: 57-68.
[http://dx.doi.org/10.1016/j.ejmech.2011.11.033] [PMID: 22182928]
[http://dx.doi.org/10.1016/j.ejmech.2011.11.033] [PMID: 22182928]
[5]
Fu J, He Z, Fu H, et al. Synthesis and evaluation of inhibitors of Mycobacterium tuberculosis UGM using bioisosteric replacement. Bioorg Med Chem 2022; 69(116896): 116896.
[http://dx.doi.org/10.1016/j.bmc.2022.116896] [PMID: 35777270]
[http://dx.doi.org/10.1016/j.bmc.2022.116896] [PMID: 35777270]
[6]
Ganihigama DU, Sureram S, Sangher S, et al. Antimycobacterial activity of natural products and synthetic agents: Pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. Eur J Med Chem 2015; 89: 1-12.
[http://dx.doi.org/10.1016/j.ejmech.2014.10.026] [PMID: 25462220]
[http://dx.doi.org/10.1016/j.ejmech.2014.10.026] [PMID: 25462220]
[7]
Hiwarale DP, Chandane WB, Deshmukh SM, et al. Green synthesis, antimycobacterial evaluation and molecular docking studies of novel 2,3-dihydro-1H-pyrazol-4-ylnaphthalene-1,4-diones. J Mol Struct 2023; 1286(135556): 135556.
[http://dx.doi.org/10.1016/j.molstruc.2023.135556]
[http://dx.doi.org/10.1016/j.molstruc.2023.135556]
[8]
Joseph J, Nagashri K, Janaki GB. Novel metal based anti-tuberculosis agent: Synthesis, characterization, catalytic and pharmacological activities of copper complexes. Eur J Med Chem 2012; 49: 151-63.
[http://dx.doi.org/10.1016/j.ejmech.2012.01.006] [PMID: 22321994]
[http://dx.doi.org/10.1016/j.ejmech.2012.01.006] [PMID: 22321994]
[9]
Kabir MS, Namjoshi OA, Verma R, et al. A new class of potential anti-tuberculosis agents: Synthesis and preliminary evaluation of novel acrylic acid ethyl ester derivatives. Bioorg Med Chem 2010; 18(12): 4178-86.
[http://dx.doi.org/10.1016/j.bmc.2010.05.016] [PMID: 20537903]
[http://dx.doi.org/10.1016/j.bmc.2010.05.016] [PMID: 20537903]
[10]
Karthik KK, Seenivasan PS, Kumar V, Mohan DT. Synthesis of quinoline coupled[1,2,3]-triazoles as a promising class of anti-tuberculosis agents. Carbohydr Res 2011; 346(14): 2084-90.
[http://dx.doi.org/10.1016/j.carres.2011.06.028] [PMID: 21767828]
[http://dx.doi.org/10.1016/j.carres.2011.06.028] [PMID: 21767828]
[11]
Naidoo K, Perumal R. Advances in tuberculosis control during the past decade. Lancet Respir Med 2023; 11(4): 311-3.
[http://dx.doi.org/10.1016/S2213-2600(23)00090-5] [PMID: 36966793]
[http://dx.doi.org/10.1016/S2213-2600(23)00090-5] [PMID: 36966793]
[12]
Daniel TM. The history of tuberculosis. Respir Med 2006; 100(11): 1862-70.
[http://dx.doi.org/10.1016/j.rmed.2006.08.006] [PMID: 16949809]
[http://dx.doi.org/10.1016/j.rmed.2006.08.006] [PMID: 16949809]
[13]
Liu Y, Zhong W, Li S. Syntheses and studies of hydantoin derivatives as potential anti-tuberculosis inhibitors. Chin Chem Lett 2012; 23(2): 133-6.
[http://dx.doi.org/10.1016/j.cclet.2011.11.017]
[http://dx.doi.org/10.1016/j.cclet.2011.11.017]
[14]
Mahajan NS, Dhawale SC. Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis. Eur J Med Chem 2015; 102: 243-8.
[http://dx.doi.org/10.1016/j.ejmech.2015.07.039] [PMID: 26280920]
[http://dx.doi.org/10.1016/j.ejmech.2015.07.039] [PMID: 26280920]
[15]
Matviiuk T, Rodriguez F, Saffon N, et al. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis. Eur J Med Chem 2013; 70: 37-48.
[http://dx.doi.org/10.1016/j.ejmech.2013.09.041] [PMID: 24140915]
[http://dx.doi.org/10.1016/j.ejmech.2013.09.041] [PMID: 24140915]
[16]
Muscia GC, Buldain GY, Asís SE. Design, synthesis and evaluation of acridine and fused-quinoline derivatives as potential anti-tuberculosis agents. Eur J Med Chem 2014; 73: 243-9.
[http://dx.doi.org/10.1016/j.ejmech.2013.12.013] [PMID: 24412719]
[http://dx.doi.org/10.1016/j.ejmech.2013.12.013] [PMID: 24412719]
[17]
World Health organization Global Tuberculosis Report Available from https://www.who.int/publications/i/item/9789240013131 2020
[18]
Onajole OK, Govender K, Govender P, et al. Pentacyclo-undecane derived cyclic tetra-amines: Synthesis and evaluation as potent anti-tuberculosis agents. Eur J Med Chem 2009; 44(11): 4297-305.
[http://dx.doi.org/10.1016/j.ejmech.2009.07.015] [PMID: 19679378]
[http://dx.doi.org/10.1016/j.ejmech.2009.07.015] [PMID: 19679378]
[19]
Patel SR, Gangwal R, Sangamwar AT, Jain R. Synthesis, biological evaluation and 3D-QSAR study of hydrazide, semicarbazide and thiosemicarbazide derivatives of 4-(adamantan-1-yl)quinoline as anti-tuberculosis agents. Eur J Med Chem 2014; 85: 255-67.
[http://dx.doi.org/10.1016/j.ejmech.2014.07.100] [PMID: 25089809]
[http://dx.doi.org/10.1016/j.ejmech.2014.07.100] [PMID: 25089809]
[20]
Seung kJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 2015; 5(9): a017863.
[http://dx.doi.org/10.1101/cshperspect.a017863]
[http://dx.doi.org/10.1101/cshperspect.a017863]
[21]
Patel SR, Gangwal R, Sangamwar AT, Jain R. Synthesis, biological evaluation and 3D QSAR study of 2,4-disubstituted quinolines as anti-tuberculosis agents. Eur J Med Chem 2015; 93: 511-22.
[http://dx.doi.org/10.1016/j.ejmech.2015.02.034] [PMID: 25747550]
[http://dx.doi.org/10.1016/j.ejmech.2015.02.034] [PMID: 25747550]
[22]
Salunke SB, Azad AK, Kapuriya NP, et al. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore. Bioorg Med Chem 2015; 23(9): 1935-43.
[http://dx.doi.org/10.1016/j.bmc.2015.03.041] [PMID: 25818768]
[http://dx.doi.org/10.1016/j.bmc.2015.03.041] [PMID: 25818768]
[23]
Tiruveedhula VVNPB, Witzigmann CM, Verma R, et al. Design and synthesis of novel antimicrobials with activity against Gram-positive bacteria and mycobacterial species, including M. tuberculosis. Bioorg Med Chem 2013; 21(24): 7830-40.
[http://dx.doi.org/10.1016/j.bmc.2013.10.011] [PMID: 24200931]
[http://dx.doi.org/10.1016/j.bmc.2013.10.011] [PMID: 24200931]
[24]
Zhang H, Chen Y, Zhang Y, et al. Identification of anti-Mycobacterium tuberculosis agents targeting the interaction of bacterial division proteins FtsZ and SepFe. Acta Pharm Sin B 2023; 13(5): 2056-70.
[http://dx.doi.org/10.1016/j.apsb.2023.01.022] [PMID: 37250168]
[http://dx.doi.org/10.1016/j.apsb.2023.01.022] [PMID: 37250168]
[25]
Keri RS, Reddy DS, Kumari S, et al. Design, synthesis, single-crystal X-ray and docking studies of imidazopyridine analogues as potent anti-TB agents. J Mol Struct 2024; 1295: 136540.
[http://dx.doi.org/10.1016/j.molstruc.2023.136540]
[http://dx.doi.org/10.1016/j.molstruc.2023.136540]
[26]
Fan C, Chen J, Xu Z, Yin P, Wu C, Sun T. Synthesis, crystal structure,anti-tuberculosis activity and toxicity prediction of N-(4-bromophenyl)-3-(5-(4-chloro-3-nitrophenyl)-1,3,4-oxadiazol-2-yl)benzenesulfonamide. J Mol Struct 2024; 1297: 136901.
[http://dx.doi.org/10.1016/j.molstruc.2023.136901]
[http://dx.doi.org/10.1016/j.molstruc.2023.136901]
[27]
Farrell KD, Gao Y, Hughes DA, et al. 3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinum. Eur J Med Chem 2023; 259(115637): 115637.
[http://dx.doi.org/10.1016/j.ejmech.2023.115637] [PMID: 37524009]
[http://dx.doi.org/10.1016/j.ejmech.2023.115637] [PMID: 37524009]
[28]
George J, Rathika Nath G, Sheena Mary Y, Shyma Mary Y, Al-Otaibi JS, Rajesh K. Synthesis, crystal structure, molecular dynamics, docking and in-vitro studies of cyclododecanonethiosemicarbazone, a promising anti tuberculosis agent. Results in Chemistry 2023; 5(100889): 100889.
[http://dx.doi.org/10.1016/j.rechem.2023.100889]
[http://dx.doi.org/10.1016/j.rechem.2023.100889]
[29]
Gollnick H, Barber J, Wilkinson RJ, Newton S, Garg A. IL-27 inhibits anti- Mycobacterium tuberculosis innate immune activity of primary human macrophages. Tuberculosis 2023; 139(102326): 102326.
[http://dx.doi.org/10.1016/j.tube.2023.102326] [PMID: 36863206]
[http://dx.doi.org/10.1016/j.tube.2023.102326] [PMID: 36863206]
[30]
Hearn MJ, Pugh CD, Cynamon MH. Synthesis of functionalized sulfonamides as antitubercular agents. Phosphorus Sulfur Silicon Relat Elem 2023; 198(9): 733-51.
[http://dx.doi.org/10.1080/10426507.2023.2196079]
[http://dx.doi.org/10.1080/10426507.2023.2196079]
[31]
Munnaluri RK, Chevula J, Patnam N, Yamini L, Manga V. One-pot synthesis, spectral characterization, biological evaluation, molecular docking studies and in silico ADME/Tox profiling of new 2,4,5 triaryl imidazole derivatives as anti tubercular agents. Indian J Tuberc 2023; 70(4): 451-9.
[http://dx.doi.org/10.1016/j.ijtb.2023.01.005] [PMID: 37968051]
[http://dx.doi.org/10.1016/j.ijtb.2023.01.005] [PMID: 37968051]
[32]
Paz JD, de Moura Sperotto DN, Ramos AS, et al. Novel 4-aminoquinolines: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation. Eur J Med Chem 2023; 245(Pt 1): 114908.
[http://dx.doi.org/10.1016/j.ejmech.2022.114908] [PMID: 36435016]
[http://dx.doi.org/10.1016/j.ejmech.2022.114908] [PMID: 36435016]
[33]
Priya MRK, Balasubramanian M, Nirmal CR, Dusthakeer A, Iyer PR. Determination of anti-tuberculosis activity of biosynthesized gold nanocompounds against M. tuberculosis H37RV. Indian J Tuberc 2023; 70(3): 329-38.
[http://dx.doi.org/10.1016/j.ijtb.2022.09.002] [PMID: 37562909]
[http://dx.doi.org/10.1016/j.ijtb.2022.09.002] [PMID: 37562909]
[34]
Rasgania J, Gavadia R, Varma-Basil M, et al. Design and synthesis of isoniazid-based pyrazolines as potential inhibitors of Mycobacterium tuberculosis with promising radical scavenging action: In-vitro and in-silico evaluations. J Mol Struct 2024; 1295(136657): 136657.
[http://dx.doi.org/10.1016/j.molstruc.2023.136657]
[http://dx.doi.org/10.1016/j.molstruc.2023.136657]
[35]
Shinde A, Thakare PP, Nandurkar Y, Bhoye M, Chavan A, Mhaske PC. Synthesis of 2-(6-substituted quinolin-4-yl)-1-(4-aryl-1H-1,2,3-triazol-1-yl) propan-2-ol as potential antifungal and antitubercular agents. Eur J Med Chem 2023; 7(100102): 100102.
[http://dx.doi.org/10.1016/j.ejmcr.2023.100102]
[http://dx.doi.org/10.1016/j.ejmcr.2023.100102]
[36]
Dhumal T. Synthesis of new amide linked biphenoloxy 1,2,3-triazoles as antitubercular and antimicrobial agents. Polycycl Aromat Compd 2023; 1-13.
[http://dx.doi.org/10.1080/10406638.2023.2225671]
[http://dx.doi.org/10.1080/10406638.2023.2225671]
[37]
Vasudevan N, Motiwala Z, Ramesh R, et al. Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: An effective strategy towards development of potent anti-tubercular agents. Eur J Med Chem 2023; 259(115633): 115633.
[http://dx.doi.org/10.1016/j.ejmech.2023.115633] [PMID: 37524010]
[http://dx.doi.org/10.1016/j.ejmech.2023.115633] [PMID: 37524010]
[38]
Central TB Division. India TB Report 2022 2023. Available from: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=5613&lid=3658
[39]
Li P, Wang B, Li G, et al. Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis. Eur J Med Chem 2020; 206: 112538.
[http://dx.doi.org/10.1016/j.ejmech.2020.112538] [PMID: 32927218]
[http://dx.doi.org/10.1016/j.ejmech.2020.112538] [PMID: 32927218]
[40]
Zhou Y, Shao M, Wang W, et al. Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy. Eur J Med Chem 2023; 245(Pt 1): 114896.
[http://dx.doi.org/10.1016/j.ejmech.2022.114896] [PMID: 36370551]
[http://dx.doi.org/10.1016/j.ejmech.2022.114896] [PMID: 36370551]
[41]
Lakshmanan M, Xavier AS. Bedaquiline – The first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm 2013; 5(4): 112-5.
[http://dx.doi.org/10.1016/j.jyp.2013.12.002] [PMID: 24563587]
[http://dx.doi.org/10.1016/j.jyp.2013.12.002] [PMID: 24563587]
[42]
Gramatica P, Cassani S, Chirico N. QSARINS-chem: Insubria datasets and new QSAR/QSPR models for environmental pollutants in QSARINS. J Comput Chem 2014; 35(13): 1036-44.
[http://dx.doi.org/10.1002/jcc.23576] [PMID: 24599647]
[http://dx.doi.org/10.1002/jcc.23576] [PMID: 24599647]
[43]
Yap CW. PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints. J Comput Chem 2011; 32(7): 1466-74.
[http://dx.doi.org/10.1002/jcc.21707] [PMID: 21425294]
[http://dx.doi.org/10.1002/jcc.21707] [PMID: 21425294]
[44]
Huang Z. Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorg Med Chem Lett 2022; 71: 128824.
[http://dx.doi.org/10.1016/j.bmcl.2022.128824]
[http://dx.doi.org/10.1016/j.bmcl.2022.128824]
[45]
Xu Zhi, Zhao S, Zaosheng Lv, et al. Benzofuran derivatives and their anti-tubercular, anti-bacterial activities. Eur J Med Chem 2019; 162: 266-76.
[http://dx.doi.org/10.1016/j.ejmech.2018.11.025]
[http://dx.doi.org/10.1016/j.ejmech.2018.11.025]
[46]
Gao C, Le C, Zhi X, et al. Recent advances of tetrazole derivatives as potential anti-tubercular and anti-malarial agents. Eur J Med Chem 2019; 163: 404-12.
[http://dx.doi.org/10.1016/j.ejmech.2018.12.001]
[http://dx.doi.org/10.1016/j.ejmech.2018.12.001]
[47]
Natarajan R, Puratchikody A, Muralidharan V, Doble M, Subramani A. 2D QSAR analysis of substituted quinoxalines for their antitubercular and antileptospiral activities. Curr Computeraided Drug Des 2019; 15(2): 182-92.
[http://dx.doi.org/10.2174/1573409914666181011145922]
[http://dx.doi.org/10.2174/1573409914666181011145922]
[48]
Docking studies and molecular dynamics simulation of triazole benzene sulfonamide derivatives with human carbonic anhydrase IX inhibition activity. RSC Advances 2021; 11(60): 38079-93.
[http://dx.doi.org/10.1039/D1RA07377J] [PMID: 35498092]
[http://dx.doi.org/10.1039/D1RA07377J] [PMID: 35498092]
[49]
Chirico N, Sangion A, Gramatica P, Bertato L, Casartelli I, Papa E. QSARINS-Chem standalone version: A new platform-independent software to profile chemicals for physico-chemical properties, fate, and toxicity. J Comput Chem 2021; 42(20): 1452-60.
[http://dx.doi.org/10.1002/jcc.26551] [PMID: 33973667]
[http://dx.doi.org/10.1002/jcc.26551] [PMID: 33973667]
[50]
Morris GM, Huey R, Olson AJ. Using AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics 2008; 24(1): 14.
[http://dx.doi.org/10.1002/0471250953.bi0814s24] [PMID: 19085980]
[http://dx.doi.org/10.1002/0471250953.bi0814s24] [PMID: 19085980]
[51]
Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: Applications of autodock. J Mol Recognit 1996; 9(1): 1-5.
[http://dx.doi.org/10.1002/(SICI)1099-1352(199601)9:1<1:AID-JMR241>3.0.CO;2-6] [PMID: 8723313]
[http://dx.doi.org/10.1002/(SICI)1099-1352(199601)9:1<1:AID-JMR241>3.0.CO;2-6] [PMID: 8723313]
[52]
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015; 1263: 243-50.
[http://dx.doi.org/10.1007/978-1-4939-2269-7_19] [PMID: 25618350]
[http://dx.doi.org/10.1007/978-1-4939-2269-7_19] [PMID: 25618350]
[53]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7(1): 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[54]
Lange C, Barry CE III, Horsburgh CR Jr. Treatments of multidrug-resistant tuberculosis: Light at the end of the tunnel. Am J Respir Crit Care Med 2022; 205(10): 1142-4.
[http://dx.doi.org/10.1164/rccm.202202-0393ED] [PMID: 35320062]
[http://dx.doi.org/10.1164/rccm.202202-0393ED] [PMID: 35320062]
[55]
Mardianingrum R, Sri RNE, Suhardiana E, Ruswanto R. Docking and molecular dynamic study of isoniazid derivatives as anti-tuberculosis drug candidate. Chem Data Collect 2021; 32: 100647.
[http://dx.doi.org/10.1016/j.cdc.2021.100647]
[http://dx.doi.org/10.1016/j.cdc.2021.100647]
[56]
Anindra SAK. Emerging impact of triazoles as anti-tubercular agent. Eur J Med Chem 2022; 238: 114454.
[http://dx.doi.org/10.1016/j.ejmech.2022.114454]
[http://dx.doi.org/10.1016/j.ejmech.2022.114454]
[57]
Alcaraz M, Sharma B, Roquet-Banères F, et al. Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis. Eur J Med Chem 2022; 239: 114531.
[http://dx.doi.org/10.1016/j.ejmech.2022.114531]
[http://dx.doi.org/10.1016/j.ejmech.2022.114531]
[58]
Subramani AK, Sivaperuman A, Natarajan R, Bhandare RR, Shaik AB. QSAR and molecular docking studies of pyrimidine-coumarin-triazole conjugates as prospective anti-breast cancer agents. Molecules 2022; 27(6): 1845.
[http://dx.doi.org/10.3390/molecules27061845] [PMID: 35335208]
[http://dx.doi.org/10.3390/molecules27061845] [PMID: 35335208]
[59]
Priya R. Biuković G, Manimekalai MSS, Lim J, Rao SPS, Grüber G. Solution structure of subunit γ (γ1-204) of the Mycobacterium tuberculosis F-ATP synthase and the unique loop of γ165-178, representing a novel TB drug target. J Bioenerg Biomembr 2013; 45(1-2): 121-9.
[http://dx.doi.org/10.1007/s10863-012-9486-4] [PMID: 23104121]
[http://dx.doi.org/10.1007/s10863-012-9486-4] [PMID: 23104121]
[60]
Desale VJ, Mali SN, Thorat BR. Yamgar, Ramesh S. Synthesis, admetSAR predictions, DPPH radical scavenging activity, and potent anti-mycobacterial studies of hydrazones of substituted 4-(anilino methyl) benzobenzohydrazides. Curr Comput Aided Drug Des 2021; 17(4): 493-503.
[http://dx.doi.org/10.2174/1573409916666200615141047]
[http://dx.doi.org/10.2174/1573409916666200615141047]
[61]
Tilal E, Malik SM, Magdi AM. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents. Bioorg Chem 2019; 88: 102969.
[http://dx.doi.org/10.1016/j.bioorg.2019.102969]
[http://dx.doi.org/10.1016/j.bioorg.2019.102969]
[62]
Alessandra CP, Marcus VNS, Maria CSL, et al. Synthesis, potent anti-TB activity against M. tuberculosis ATTC 27294, crystal structures and complex formation of selected 2-arylidenehydrazinylbenzothiazole derivatives. J Mol Struct 2019; 1178: 655-68.
[http://dx.doi.org/10.1016/j.molstruc.2018.10.030]
[http://dx.doi.org/10.1016/j.molstruc.2018.10.030]
[63]
Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 2011; 469(7331): 483-90.
[http://dx.doi.org/10.1038/nature09657] [PMID: 21270886]
[http://dx.doi.org/10.1038/nature09657] [PMID: 21270886]
[64]
Sarathy JP, Gruber G, Dick T. Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline. Antibiotics 2019; 8(4): 261.
[http://dx.doi.org/10.3390/antibiotics8040261] [PMID: 31835707]
[http://dx.doi.org/10.3390/antibiotics8040261] [PMID: 31835707]
[65]
Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: Current status and future perspectives. J Glob Antimicrob Resist 2021; 25: 48-59.
[http://dx.doi.org/10.1016/j.jgar.2021.02.017] [PMID: 33684606]
[http://dx.doi.org/10.1016/j.jgar.2021.02.017] [PMID: 33684606]
[66]
Traoré AN, Rikhotso MC, Banda NT, et al. Effectiveness of the novel anti-TB bedaquiline against drug-resistant TB in Africa: A systematic review of the literature. Pathogens 2022; 11(6): 636.
[http://dx.doi.org/10.3390/pathogens11060636] [PMID: 35745490]
[http://dx.doi.org/10.3390/pathogens11060636] [PMID: 35745490]
[67]
Xu J, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Comparative efficacy of the novel diarylquinoline tbaj-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis. Antimicrob Agents Chemother 2021; 65(4): e02418-20.
[http://dx.doi.org/10.1128/AAC.02418-20] [PMID: 33526488]
[http://dx.doi.org/10.1128/AAC.02418-20] [PMID: 33526488]
[68]
Scior T, Meneses MI, Garcés ESJ, Domeyer D, Laufer S. Antitubercular isoniazid and drug resistance of mycobacterium tuberculosis — a review. Arch Pharm 2002; 335(11-12): 511-25.
[http://dx.doi.org/10.1002/ardp.200290005] [PMID: 12596216]
[http://dx.doi.org/10.1002/ardp.200290005] [PMID: 12596216]
[69]
Goldman AL, Braman SS. Isoniazid: A review with emphasis on adverse effects. Chest 1972; 62(1): 71-7.
[http://dx.doi.org/10.1378/chest.62.1.71] [PMID: 4339326]
[http://dx.doi.org/10.1378/chest.62.1.71] [PMID: 4339326]
[70]
Sulis G, Pai M. Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLoS Med 2020; 17(1): e1003023.
[http://dx.doi.org/10.1371/journal.pmed.1003023] [PMID: 31961857]
[http://dx.doi.org/10.1371/journal.pmed.1003023] [PMID: 31961857]
[71]
Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013; 57(2): 893-900.
[http://dx.doi.org/10.1128/AAC.01024-12] [PMID: 23208715]
[http://dx.doi.org/10.1128/AAC.01024-12] [PMID: 23208715]
[72]
Aït Moussa L, El Bouazzi O, Serragui S, Soussi Tanani D, Soulaymani A, Soulaymani R. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: A retrospective analysis. Ther Adv Drug Saf 2016; 7(6): 239-47.
[http://dx.doi.org/10.1177/2042098616667704] [PMID: 27904742]
[http://dx.doi.org/10.1177/2042098616667704] [PMID: 27904742]
[73]
Van Deun A, Bola V, Lebeke R, et al. Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings. JAC-Antimicrobial Resistance 2022; 4(2): dlac037.
[http://dx.doi.org/10.1093/jacamr/dlac037] [PMID: 35415609]
[http://dx.doi.org/10.1093/jacamr/dlac037] [PMID: 35415609]
[74]
Tantry SJ, Markad SD, Shinde V, et al. Discovery of imidazo[1,2- a]pyridine ethers and squaramides as selective and potent inhibitors of mycobacterial adenosine triphosphate (ATP) synthesis. J Med Chem 2017; 60(4): 1379-99.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01358] [PMID: 28075132]
[http://dx.doi.org/10.1021/acs.jmedchem.6b01358] [PMID: 28075132]
Related Books
Industrial Applications of Soil Microbes
The Future of Agriculture: IoT, AI and Blockchain Technology for Sustainable Farming
Handbook of Integrated Weed Management for Major Field Crops
Practical Biochemistry
Anticancer Drugs Sourced from Marine Life
Opportunities for Biotechnology Research and Entrepreneurship
Diseases of Ornamental, Aromatic and Medicinal Plants
Diabetes and Breast Cancer: An Analysis of Signaling Pathways
Fundamentals of Cellular and Molecular Biology
Industrial Applications of Soil Microbes
Article Metrics
27
2
